William T. End Sells 5,000 Shares of Idexx Laboratories Inc. (IDXX) Stock
Idexx Laboratories Inc. (NASDAQ:IDXX) Director William T. End sold 5,000 shares of the stock in a transaction that occurred on Tuesday, November 8th. The stock was sold at an average price of $109.87, for a total value of $549,350.00. Following the transaction, the director now owns 48,654 shares in the company, valued at approximately $5,345,614.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Idexx Laboratories Inc. (NASDAQ:IDXX) opened at 108.76 on Friday. The stock has a 50 day moving average price of $110.59 and a 200 day moving average price of $100.37. The stock has a market cap of $9.75 billion, a P/E ratio of 46.32 and a beta of 0.48. Idexx Laboratories Inc. has a 52-week low of $63.48 and a 52-week high of $117.84.
Idexx Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, November 1st. The company reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.60 by $0.02. The firm had revenue of $448.30 million for the quarter, compared to analysts’ expectations of $448.60 million. Idexx Laboratories had a negative return on equity of 788.91% and a net margin of 12.36%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.48 EPS. On average, equities research analysts forecast that Idexx Laboratories Inc. will post $2.38 EPS for the current year.
A number of equities analysts have issued reports on IDXX shares. Zacks Investment Research downgraded Idexx Laboratories from a “hold” rating to a “sell” rating in a research report on Friday, October 28th. Canaccord Genuity reiterated a “buy” rating and set a $120.00 price target on shares of Idexx Laboratories in a research report on Monday, August 22nd. Bank of America Corp. reiterated a “neutral” rating on shares of Idexx Laboratories in a research report on Thursday, September 29th. Stifel Nicolaus increased their price target on Idexx Laboratories from $120.00 to $125.00 and gave the stock a “buy” rating in a research report on Tuesday, August 16th. Finally, Northcoast Research upgraded Idexx Laboratories from a “sell” rating to a “neutral” rating in a research report on Wednesday, August 3rd. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $105.20.
Institutional investors have recently modified their holdings of the stock. Canada Pension Plan Investment Board bought a new position in shares of Idexx Laboratories during the first quarter valued at about $196,000. Goldman Sachs Group Inc. boosted its position in shares of Idexx Laboratories by 43.2% in the first quarter. Goldman Sachs Group Inc. now owns 391,756 shares of the company’s stock valued at $30,683,000 after buying an additional 118,115 shares during the period. Geode Capital Management LLC boosted its position in shares of Idexx Laboratories by 4.0% in the first quarter. Geode Capital Management LLC now owns 576,331 shares of the company’s stock valued at $45,138,000 after buying an additional 22,351 shares during the period. Renaissance Technologies LLC boosted its position in shares of Idexx Laboratories by 242.6% in the first quarter. Renaissance Technologies LLC now owns 437,504 shares of the company’s stock valued at $34,265,000 after buying an additional 309,804 shares during the period. Finally, Bayesian Capital Management LP bought a new position in shares of Idexx Laboratories during the first quarter valued at about $368,000. Hedge funds and other institutional investors own 91.54% of the company’s stock.
About Idexx Laboratories
Receive News & Stock Ratings for Idexx Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories Inc. and related stocks with our FREE daily email newsletter.